

Express Mail No. EV 330857135

PATENT

Mailed: August 19, 2003

Attorney Docket No.: 015280-257300  
DHHS Ref. E-148-1998/1-US-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GEORGE N. PAVLAKIS

Application No.:

Filed: Herewith

For: MOLECULAR CLONES WITH  
MUTATED HIV GAG/POL, SIV GAG  
AND SIV ENV GENES

Examiner:

Art Unit:


INFORMATION DISCLOSURE  
STATEMENT  
UNDER 37 CFR §1.97 AND §1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants bring to the Examiner's attention the related patent application, U.S. Serial No. 09/872,733 filed June 1, 2001, which is relied upon for an earlier filing date under 35 U.S.C. §120. Applicants respectfully request that the references supplied in compliance with 37 C.F.R. §1.97 in said parent application, as well as those cited during its examination, be made of record. For the convenience of the Examiner, copies of the Information Disclosure Statements dated July 16, 2001, October 15, 2001 and January 31, 2003, as well as the forms PTO-1449 and PTO/SB/08B, filed in the parent application are attached. Copies of the documents will be found in said parent application.

Respectfully submitted,



Jean M. Lockyer, Ph.D.  
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
(415) 576-0200  
Fax (415) 576-0300  
JML/mcd - 60019445 v1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 015280-257100US

Assistant Commissioner for Patents  
Washington, D.C. 20231

On 31 Jan: 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Malinda Adams

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

George N. Pavlakis

Application No.: 09/872,733

Filed: June 1, 2001

For: MOLECULAR CLONES WITH  
MUTATED HIV GAG/POL, SIV GAG  
AND SIV ENV GENES

Examiner: Dave Trong Nguyen

Art Unit: 1632

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The reference cited on attached form PTO/SB/08B is being called to the attention of the Examiner. A copy of the reference is enclosed.

Also enclosed is a copy of the Search/Examination report issued in a corresponding PCT application.

It is respectfully requested that the cited reference be expressly considered during the prosecution of this application, and the reference be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee to Deposit Account No. 20-1430 in accordance with the accompanying Fee Transmittal PTO/SB/17. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Jean M. Lockyer, Ph.D.  
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
JML:mcd

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Unsaved Document

Docket No. 2026-4287US1

<b>Applicant(s)</b>	<b>:</b>	<b>George Pavlakis</b>	<b>Group Art Unit: Beena Puri, Ph.D.</b>
<b>Serial No</b>	<b>:</b>	<b>09/872,733</b>	<b>Examiner: 1633</b>
<b>Filed</b>	<b>:</b>	<b>June 1, 2001</b>	
<b>For</b>	<b>:</b>	<b>MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV GAG AND SIV ENV GENES</b>	

COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

This Supplemental Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:  
  
\_\_\_\_\_  
  
\_\_\_\_\_
2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.

4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:
- ☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of the above-identified application for filing date of the continued prosecution application filed on \_\_\_\_\_; or
  - ☐ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
  - ☒ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office Action on the merits, whichever event occurred last.
5. ☐ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6. ☐ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
- ☐ A check in the amount of \$240.00 is enclosed in payment of the fee.
  - ☐ Charge the fee to Deposit Account No. 13-4500. Order No. \_\_\_\_\_. A  
DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
- a. ☐ one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
  - b. ☐ the attached petition requesting consideration of this Information Disclosure Statement; and
  - c. ☐ the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in paragraph 10 below.
8. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with:
- a. ☐ 37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;
  - b. ☐ 37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To withdraw Application From Issue.
  - c. ☐ The fee due under 37 C.F.R. §1.17(i)(1) is paid as set forth in paragraph 10 below.

9. ☐ I hereby certify that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after make reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

10. ☐ A check in the amount of \$130.00 is enclosed in payment of the fee due under C.F.R. §1.17(i)(1).

☐ Charge the fee due under C.F.R. §1.17(i)(1) to Deposit Account No. 13-4500. Order No. \_\_\_\_\_ A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

☒ The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500. Order No. 2026-4287US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: October 15, 2001

By: \_\_\_\_\_

Mary J. Morry  
Registration No. 34,398

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 Facsimile

FORM: IDS.NY  
Rev. 05/26/98

<b>FORM PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b>		Attorney Docket: 2026-4287US1	Serial No.: 09/872,733			
		Applicant: George Pavlakis				
		Filing Date: June 1, 2001	Group Art Unit: 1633			
<b>U.S. PATENT DOCUMENTS</b>						
<b>Examiner Initial</b>	<b>Patent Number</b>	<b>Issue Date</b>	<b>Name</b>	<b>Class</b>	<b>Sub-Class</b>	<b>Filing Date</b>

<b>FOREIGN PATENT DOCUMENTS</b>						
<b>Examiner Initial</b>	<b>Patent Number</b>	<b>Issue Date</b>	<b>Country</b>	<b>Class</b>	<b>Sub-Class</b>	<b>Translation</b>
	WO 98/17816	April 30, 1998	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 98/46083	October 22, 1998	PCT			
	WO 99/04026	January 28, 1999	PCT			
	WO 99/15641	April 1, 1999	PCT			
	WO 99/30742	June 24, 1999	PCT			
	WO 99/51754	October 14, 1999	PCT			
	WO 00/65076	November 2, 2000	PCT			

<b>OTHER DOCUMENTS (continued)</b>	
	Akkin, R.K. et al., "High-Efficiency Gene Transfer into CD34+ Cells with a Human Immunodeficiency Virus Type 1-Based Retroviral Vector Pseudotyped with Vesicular Stomatitis Virus Envelope Glycoprotein G", J. Virology, 70:2581-2585 (1996)
	Amado, R.G. et al., "Lentiviral Vectors – the Promise of Gene Therapy Within Reach?", Science, 285:674-676 (July 1999)
	Donahue, R.E. et al., "Transplantation of Immunoselected CD34+ Cells Transduced with a EGFP-Expressing Lentiviral Vector in Non-Human Primates", Blood, 92 (Suppl. 1):383b, Abstract #4648.5 (1998)
	Fox, J.L., "Researchers wary of fear-based ban on lentivirus gene therapy", Nature Biotechnology, 16:407-408 (1998)
	Goldman, M.J. et al., "Lentiviral Vectors for Gene Therapy of Cystic Fibrosis", Human Gene Therapy, 8:2261-2268 (1997)
	Kafri, T. et al., "Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors", Nature Genetics, 17:314-317 (1997)
	Kafri, T. et al., "A Packaging Cell Line for Lentivirus Vectors", J. Virol., 73:576-584 (1999)
	Kim, V.N. et al., "Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1", J. Virol., 72:811-816 (1998)
	Klimatcheva, E. et al., "Lentiviral Vectors and Gene Therapy", Frontiers in Bioscience, 4:d481-496 (June 1999)
	Kotsopoulou, E. et al., "A Rev-Independent Human Immunodeficiency Virus Type 1 (HIV-1)-Based Vector That Exploits a Codon-Optimized HIV-1 gag-pol Gene", J. Virol., 74:4839-4852 (2000)
	Miyoshi, H. et al., "Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector", Proc. Natl. Acad. Sci. USA, 94:10319-10323 (1997)

<b>Examiner</b>	<b>Date Considered</b>
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	



<b>FORM PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b>	Attorney Docket: 2026-4287US1	Serial No.: 09/872,733
	Applicant: George Pavlakis	
	Filing Date: June 1, 2001	Group Art Unit: 1633

OTHER DOCUMENTS (continued)	
	Miyoshi, H. et al., "Development of a Self-Inactivating Lentivirus Vector", J. Virol., 72:8150-8157 (1998)
	Miyoshi, H. et al., "Transduction of Human CD34 <sup>+</sup> Cells That Mediate Long-Term Engraftment of NOD/SCID Mice by HIV Vectors", Science, 283:682-686 (1999)
	Naldini, L. et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector", Science, 272:263-267 (1996)
	Naviaux, R.K. et al., "The pCL Vector System: Rapid Production of Helper-Free, High-Titer, Recombinant Retroviruses", J. Virol., 70:5701-5705 (1996)
	Poeschla, E.M. et al., "Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors", Nature Med., 4:354-357 (1998)
	Reynolds, P.N. et al., "Viral vectors show promise in Colorado", Nature Biotechnology, 16:422-423 (1998)
	Soneoka, Y. et al., "A transient three-plasmid expression system for the production of high titer retroviral vectors", Nuc. Acids Res., 23:628-633 (1995)
	Srinivasakumar, N. et al., "The Effect of Viral Regulatory Protein Expression on Gene Delivery by Human Immunodeficiency Virus Type 1 Vectors Produced in Stable Packaging Cell Lines", J. Virol., 71:5841-5848 (1997)
	Sutton, R.E. et al., "Human Immunodeficiency Virus Type 1 Vectors Efficiently Transduce Human Hematopoietic Stem Cells", J. Virol., 72:5781-5788 (1998)
	Takahashi, M. et al., "Rescue from Photoreceptor Degeneration in the <i>rd</i> Mouse by Human Immunodeficiency Virus Vector-Mediated Gene Transfer", J. Virol., 73:7812-7816 (September 1999)
	Uchida, N. et al., "HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G <sub>0</sub> /G <sub>1</sub> human hematopoietic stem cells", Proc. Natl. Acad. Sci. USA, 95:11939-11944 (1998)
	Vinner, L. et al., "Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons", Vaccine, 17:2166-2175 (1999)
	Wagner, R. et al., "Rev-Independent Expression of Synthetic <i>gag-pol</i> Genes of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus: Implications for the Safety of Lentiviral Vectors", Human Gene Therapy, 11:2403-2413 (2000)
	White, S.M. et al., "Lentivirus Vectors Using Human and Simian Immunodeficiency Virus Elements", J. Virol., 73:2832-2840 (1999)
	Wolff, J.A. et al., "The Cambrian period of nonviral gene delivery", Nature Biotechnology, 16:421-422 (1998)
	Zufferey, R. et al., "Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo", Nature Biotechnology, 15:871-875 (1997)
	Zufferey, R. et al., "Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery", 72:9873-9880 (1998)
Examiner	Date Considered
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

PATENT

Docket No. 2026-4287US1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicant(s)</b>	<b>:</b>	<b>George Pavlakis</b>	<b>Group Art Unit: To Be Assigned</b>
<b>Serial No</b>	<b>:</b>	<b>09/872,733</b>	<b>Examiner: To Be Assigned</b>
<b>Filed</b>	<b>:</b>	<b>June 1, 2001</b>	
<b>For</b>	<b>:</b>	<b>MOLECULAR CLONES WITH MUTATED HIV GAG/POL, SIV GAG AND SIV ENV GENES</b>	

## **INFORMATION DISCLOSURE STATEMENT**

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

**Sir:**

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☒ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:  
  
\_\_\_\_\_  
  
\_\_\_\_\_
2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.
4. ☒ No fee is due under 37 C.F.R. § 1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:


- ☒ 37 C.F.R. §1.97(b)(1), within three months of the filing date of the above-identified application for filing date of the continued prosecution application filed on June 1, 2001; or
- ☐ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
- ☒ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office Action on the merits, whichever event occurred last.
5. ☐ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6. ☐ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
- ☐ A check in the amount of \$240.00 is enclosed in payment of the fee.
- ☐ Charge the fee to Deposit Account No. 13-4500. Order No. \_\_\_\_\_. A  
DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
- a. ☐ one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
- b. ☐ the attached petition requesting consideration of this Information Disclosure Statement; and
- c. ☐ the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in paragraph 10 below.
8. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with:
- a. ☐ 37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;
- b. ☐ 37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To withdraw Application From Issue.
- c. ☐ The fee due under 37 C.F.R. §1.17(i)(1) is paid as set forth in paragraph 10 below.
9. ☐ I hereby certify that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

- ☐ I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after make reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
10. ☐ A check in the amount of \$130.00 is enclosed in payment of the fee due under C.F.R. §1.17(i)(1).
- ☐ Charge the fee due under C.F.R. §1.17(i)(1) to Deposit Account No. 13-4500. Order No. \_\_\_\_\_ A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500. Order No. 2026-4287US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: July 16, 2001

By: \_\_\_\_\_

  
Mary J. Morry  
Registration No. 34,398

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 Facsimile

FORM: IDS.NY  
Rev. 05/26/98

<b>FORM PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b>			Attorney Docket: 2026-4287US1		Serial No.: 09/872,733	
			Applicant: George Pavlakis			
			Filing Date: June 1, 2001		Group Art Unit: To Be Assigned	
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initial	Patent Number	Issue Date	Name	Class	Sub-Class	Filing Date
	6,174,666 B1	Jan 16, 2001	Pavlakis and Felber			3/27/92
	5,972,596	Oct 29, 1999	Pavlakis and Felber			1994
	5,965,726	Oct 12, 1999	Pavlakis and Felber			5/2/97
	5,786,464	Jul 28, 1998	Seed and Haas			7/28/98
	5,795,737	Aug 18, 1998	Seed			9/22/95
	6,114,148	Sep 05, 2000	Seed and Haas			

<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initial	Patent Number	Issue Date	Country	Class	Sub-Class	Translation
	WO 90/11092	Oct. 1990	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 93/20212	Oct 14, 1993	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 96/09378	Mar 28, 1996	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 97/11086	Mar 27, 1997	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 98/12207	Mar 26, 1998	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 98/34640	Aug 13, 1998	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 00/39302	Jul 6, 2000	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 00/39303	Jul 6, 2000	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 00/39304	Jul 6, 2000	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 99/61596	Dec. 2, 1999	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No

<b>OTHER DOCUMENTS (continued)</b>	
	Nappi F, Schneider R, Zolotukhin A, Smulevitch S, Michalowski D, Bear J, Felber BK, and Pavlakis GN. "Identification of a Novel Posttranscriptional Regulatory Element by Using a rev- and RRE-Mutated Human Immunodeficiency Virus Type 1 DNA Proviral Clone as a Molecular Trap." J Virol. 2001 May;75(10):4558-69.
	Qiu JT, Liu B, Tian C, Pavlakis GN, Yu XF. "Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway." J Virol. 2000 Jul;74(13):5997-6005.
	Qiu JT, Song R, Dettenhofer M, Tian C, August T, Felber BK, Pavlakis GN, Yu XF. "Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses." J Virol. 1999 Nov;73(11):9145-52.

Examiner	Date Considered
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

<b>FORM PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b>	Attorney Docket: 2026-4287US1	Serial No.: 09/872,733
	Applicant: George Pavlakis	
	Filing Date: June 1, 2001	Group Art Unit: To Be Assigned

OTHER DOCUMENTS (continued)	
	Schneider R, Campbell M, Nasioulas G, Felber BK, Pavlakis GN. "Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation." J Virol. 1997 Jul;71(7):4892-903.
	Afonina E, Neumann M, Pavlakis GN. "Preferential binding of poly(A)-binding protein 1 to an inhibitory RNA element in the human immunodeficiency virus type 1 gag mRNA." J Biol Chem. 1997 Jan 24;272(4):2307-11.
	Schwartz S, Campbell M, Nasioulas G, Harrison J, Felber BK, Pavlakis GN. "Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression." J Virol. 1992 Dec.; 66 (12):7176-82.
	Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J. "Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage." J Virol. 1998 Feb; 72(2):1497-503.
	Haas J, Park EC, Seed B. "Codon usage limitation in the expression of HIV-1 envelope glycoprotein." Curr Biol. 1996 Mar 1;6(3):315-24.
	Ikemura, T. "Codon Usage and tRNA Content in Unicellular and Multicellular Organisms." Mol. Biol. Evol. 2(1):13-34 (1985)
	T. Maruyama et al., "Codon usage tabulated from the GenBank genetic sequence data", Nucl. Acids Res. 14:r151-r197 (1986)
	S. Aota et al., "Codon usage tabulated from the GenBank genetic sequence data", Nucl. Acids Res. 16:r315-r402 (1988)
	Shiver, et al., "DNA Vaccine-Mediated Cellular Immunity Against HIV-1 gag And env," abstract from the Conference on Advances in aids Vaccine Development; 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS (NCVDGs), February 11-15, 1996
	Albert B Sabin, "Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry", Proc. Natl. Acad. Sci. USA, 89:8852-8855 (September 1992) ("Reference 1")
	Saladin Osmanov et al., "HIV-1 Genetic Variability: Implications for the Development of HIV Vaccines", Antibiotics and Chemotherapy, 48:30-38 (1996) ("Reference 2")
	Kavita S. Lole, et al., "Full-Length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination", Journal of Virology, 73:152-160 (January 1999) ("Reference 3")
	"Nikkei Biotechnology Annual Report '98", Ed. NIKKEI BIOTECH, (Nov. 30, 1997), Nikkei Business Publications, Inc., p. 214 (English translation of table on page 214, lines 30-35 entitled "The recent stream of research and development on AIDS") ("Reference 4")
	R.I. Connor, et al., "Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines", Journal of Virology, 72:1552-1576 (February 1998) ("Reference 5")
	"Nikkei Biotechnology Annual Report '97", Ed. NIKKEI BIOTECH, (Nov. 30, 1996), Nikkei Business Publications, Inc., p. 246 (English translation of a table on page 246, lines 43-46 entitled "The recent stream of biotechnological research on AIDS") ("Reference 6")

Examiner	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

<b>FORM PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b>	Attorney Docket: 2026-4287US1	Serial No.: 09/872,733
	Applicant: George Pavlakakis	
	Filing Date: June 1, 2001	Group Art Unit: To Be Assigned

OTHER DOCUMENTS (continued)	
	"Nikkei Biotechnology Annual Report '99", Ed. NIKKEI BIOTECH, (Nov. 30, 1998), Nikkei Business Publications, Inc., p. 79 (English translation of table on p. 79, lines 14-17 entitled "The main stream of research and development on AIDS") ("Reference 7")
	Ulmer JB., Donnelly JJ., Parker SE., Rhodes GH., Felgner PL., Dwarki VJ., Gromkowski SH., Deck RR., DeWitt CM., Friedman A., Hawe LA., Leander KR., Martinez D., Perry HC., Shiver JW., Montgomery DL., Liu MA. "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein." <i>Science</i> 259:1745-1748 (March 19, 1993)
	Afonina E., Stauber R., Pavlakakis GN. "The Human Poly(A)-binding Protein 1 Shuttles between the Nucleus and the Cytoplasm", <i>The Journal of Biological Chemistry</i> , 273:13015-13021 (May 22, 1998)
	Solomin L., Felber BK., Pavlakakis GN. "Different Sites of Interaction for Rev, Tev, and Rex Proteins within the Rev-Responsive Element of Human Immunodeficiency Virus Type 1", <i>Journal of Virology</i> , 64:6010-6017 (Dec. 1990)
	Benko DM., Robinson R., Solomin, L., Mellini M., Felber BK., Pavlakakis, GN. "Binding of Trans-Dominant Mutant Rev Protein of Human Immunodeficiency Virus Type 1 to the Cis-Acting Rev-Responsive Element Does Not Affect the Fate of Viral mRNA", <i>The New Biologist</i> , 2:1111-1122 (Dec. 1990)
	Schwartz S., Felber BK., Pavlakakis GN., "Distinct RNA Sequences in the gag Region of Human Immunodeficiency Virus Type 1 Decrease RNA Stability and Inhibit Expression in the Absence of Rev Protein", <i>Journal of Virology</i> , 66:150-159 (Jan. 1992)
	D'Agostino DM., Felber BK., Harrison JE., Pavlakakis GN. "The Rev Protein of Human Immunodeficiency Virus Type 1 Promotes Polysomal Association and Translation of gag/pol and vpu/env mRNAs", <i>Molecular and Cellular Biology</i> , 12:1375-1386 (March 1992)
	Myers G., Pavlakakis GN. "Evolutionary Potential of Complex Retroviruses", <i>The Retroviridae</i> , 1:51-105 (1992)
	Zolotukhin AS., Valentin A., Pavlakakis GN., Felber BK. "Continuous Propagation of RRE(+) and Rev(+)RRE(+) Human Immunodeficiency Virus Type 1 Molecular Clones Containing a cis-Acting Element of Simian Retrovirus Type 1 in Human Peripheral Blood Lymphocytes", <i>Journal of Virology</i> , 68:7944-7952 (Dec. 1994)
	Tan W., Felber BK., Zolotukhin AS., Pavlakakis GN., Schwartz S. "Efficient Expression of the Human Papillomavirus Type 16 L1 Protein in Epithelial Cells by Using Rev and the Rev-Responsive Element of Human Immunodeficiency Virus or the cis-Acting Transactivation Element of Simian Retrovirus Type 1", <i>Journal of Virology</i> , 69:5607-5620 (Sept. 1995)
	Wolff JA., Malone RW., Williams P., Chong W., Acsadi G., Jani A., Felgner PL. "Direct Gene Transfer into Mouse Muscle in Vivo" <i>Science</i> , 247:1465-1468 (March 23, 1990)
	Wolff JA., Ludtke JJ., Acsadi G., Williams P., Jani A. "Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle", <i>Human Molecular Genetics</i> , 1(6):363-369 (1992)
	Egan MA., Charini WA., Kuroda MJ., Schmitz JE., Racz P., Tenner-Racz K., Manson K., Wyand M., Lifton MA., Nickerson CE., Fu T., Shiver JW., Letvin NL. "Simian Immunodeficiency Virus (SIV) gag DNA-Vaccinated Rhesus Monkeys Develop Secondary Cytotoxic T-Lymphocyte Responses and Control Viral Replication after Pathogenic SIV Infection" <i>Journal of Virology</i> , 74(16):7485-7495 (Aug. 2000)

Examiner	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	